Matthias Barz Selected Research

Neoplasms (Cancer)

4/2024	Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment.
1/2022	From Self-Organization to Tumor-Immune Therapy: How Things Started and How They Evolved.
1/2022	Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225Ac, and beta-particle emitter, 177Lu.
11/2021	Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin.
10/2021	Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression.
1/2021	Delivery of siHIF-1α to Reconstruct Tumor Normoxic Microenvironment for Effective Chemotherapeutic and Photodynamic Anticancer Treatments.
12/2020	Influence of Riboflavin Targeting on Tumor Accumulation and Internalization of Peptostar Based Drug Delivery Systems.
1/2020	Trans-Cyclooctene-Functionalized PeptoBrushes with Improved Reaction Kinetics of the Tetrazine Ligation for Pretargeted Nuclear Imaging.
2/2019	Multistage rocket: integrational design of a prodrug-based siRNA delivery system with sequential release for enhanced antitumor efficacy.
1/2019	Nanomedicine and macroscale materials in immuno-oncology.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthias Barz Research Topics

Disease

19	Neoplasms (Cancer) 04/2024 - 09/2010
2	Tuberculosis (Tuberculoses) 01/2023 - 01/2022
2	Melanoma (Melanoma, Malignant) 10/2021 - 02/2014
2	Inflammation (Inflammations) 10/2021 - 10/2017
2	Adenocarcinoma 10/2012 - 10/2009
1	Lung Neoplasms (Lung Cancer) 04/2024
1	Communicable Diseases (Infectious Diseases) 08/2023
1	Nervous System Diseases (Neurological Disorders) 01/2023
1	Head and Neck Neoplasms (Head and Neck Cancer) 11/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Chronic Hepatitis B 01/2021
1	Hypersensitivity (Allergy) 12/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Granuloma 01/2018
1	Fibrosarcoma 01/2018
1	Bacterial Infections (Bacterial Infection) 01/2018
1	Infections 01/2018
1	Liver Diseases (Liver Disease) 10/2017
1	Hepatitis 10/2017
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017
1	Prostatic Neoplasms (Prostate Cancer) 01/2017
1	Carcinoma (Carcinomatosis) 09/2010

Drug/Important Bio-Agent (IBA)

11	PolymersIBA 01/2022 - 10/2009
2	IronIBA 04/2024 - 10/2021
2	VaccinesIBA 08/2023 - 02/2018
2	Messenger RNA (mRNA)IBA 08/2023 - 01/2023
2	Radioisotopes (Radionuclides)IBA 01/2022 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2019
2	MicellesIBA 10/2021 - 10/2021
2	Small Interfering RNA (siRNA)IBA 01/2021 - 02/2019
2	Riboflavin (Vitamin B2)FDA LinkGeneric 12/2020 - 01/2017
2	riboflavin-binding proteinIBA 12/2020 - 01/2017
2	Liposomes (Liposome)IBA 12/2019 - 01/2018
2	Peptides (Polypeptides)IBA 02/2019 - 02/2014
2	Drug CarriersIBA 01/2018 - 01/2017
2	Folic Acid (Vitamin M)FDA LinkGeneric 10/2014 - 09/2010
2	hydroxypropyl methacrylateIBA 05/2014 - 10/2012
1	CrizotinibIBA 04/2024
1	Tyrosine Kinase InhibitorsIBA 04/2024
1	Lipid NanoparticlesIBA 08/2023
1	pretomanidIBA 01/2023
1	Polyglutamic Acid (Polyglutamate)IBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 11/2021
1	Ion Channels (Ion Channel)IBA 11/2021
1	Adenosine Monophosphate (AMP)IBA 10/2021
1	Cyclic NucleotidesIBA 10/2021
1	Angiotensin Receptor AntagonistsIBA 01/2021
1	candesartanIBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	OligodeoxyribonucleotidesIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Aligeron (AS 2)IBA 01/2020
1	EsterasesIBA 02/2019
1	ProdrugsIBA 02/2019
1	CamptothecinIBA 02/2019
1	Immunomodulating AgentsIBA 01/2019
1	MetalsIBA 01/2019
1	DuxonIBA 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	Biocompatible Materials (Biomaterials)IBA 01/2018
1	histidine-rich proteinsIBA 01/2018
1	Carbon Tetrachloride (Tetrachloromethane)IBA 10/2017
1	SelectinsIBA 10/2017
1	Concanavalin AIBA 10/2017
1	AntibodiesIBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2012

Therapy/Procedure

10	Therapeutics 04/2024 - 07/2014
4	Immunotherapy 04/2024 - 05/2014
1	Ligation 01/2022
1	Radiotherapy 01/2022
1	Precision Medicine 11/2021
1	Drug Therapy (Chemotherapy) 11/2021
1	Relaxation Therapy (Relaxation Technique) 01/2021
1	Immunomodulation 10/2017